8X7A image
Entry Detail
PDB ID:
8X7A
EMDB ID:
Title:
Treprostinil bound Prostacyclin Receptor G protein complex
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2023-11-23
Release Date:
2024-03-06
Method Details:
Experimental Method:
Resolution:
2.56 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(s) subunit alpha isoforms short,GNAS complex locus
Chain IDs:A
Chain Length:249
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Chain IDs:B
Chain Length:350
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2
Chain IDs:C (auth: G)
Chain Length:71
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Nanobody35
Chain IDs:D (auth: N)
Chain Length:134
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Prostacyclin receptor
Chain IDs:E (auth: R)
Chain Length:386
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Molecular recognition and activation of the prostacyclin receptor by anti-pulmonary arterial hypertension drugs.
Sci Adv 10 eadk5184 eadk5184 (2024)
PMID: 38335293 DOI: 10.1126/sciadv.adk5184

Abstact

The prostacyclin (PGI2) receptor (IP) is a Gs-coupled receptor associated with blood pressure regulation, allergy, and inflammatory response. It is a main therapeutic target for pulmonary arterial hypertension (PAH) and several other diseases. Here we report cryo-electron microscopy (cryo-EM) structures of the human IP-Gs complex bound with two anti-PAH drugs, treprostinil and MRE-269 (active form of selexipag), at global resolutions of 2.56 and 2.41 angstrom, respectively. These structures revealed distinct features governing IP ligand binding, receptor activation, and G protein coupling. Moreover, comparison of the activated IP structures uncovered the mechanism and key residues that determine the superior selectivity of MRE-269 over treprostinil. Combined with molecular docking and functional studies, our structures provide insight into agonist selectivity, ligand recognition, receptor activation, and G protein coupling. Our results provide a structural template for further improving IP-targeting drugs to reduce off-target activation of prostanoid receptors and adverse effects.

Legend

Protein

Chemical

Disease

Primary Citation of related structures